All In Biotech

Drug Trial Radar · NCT07263230

The Safety and Efficacy of Roflumilast Foam in HS

An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Aug 2028

Study completion May 2029

Sponsor

Lead sponsor
Beth Israel Deaconess Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • Roflumilast 0.3% topical foamDrug

    Roflumilast foam, 0.3%, is a phosphodiesterase 4 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16.Time frame: Baseline and Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.